Creative Planning
CTMX icon

Creative Planning’s CytomX Therapeutics CTMX Stock Holding History

Creative Planning’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,505
Closed -$49.4K – 4327
2026
Q1 		$49.4K Buy
+10,505
New +$53.3K ﹤0.01% 3985
2024
Q4 		– Sell
-107,000
Closed -$126K – 3611
2024
Q3 		$126K Hold
107,000
– – ﹤0.01% 2971
2024
Q2 		$131K Buy
+107,000
New +$213K ﹤0.01% 2787

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Creative Planning's CTMX Position: Q2 2026 in Review

Creative Planning sold out of CytomX Therapeutics (CTMX) in Q2 2026, closing a stake of 10,505 shares — an estimated $49.4K sold.

Creative Planning first reported a position in CTMX in Q2 2024 and held it in 3 quarters. The position peaked at $131K in Q2 2024. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Creative Planning reported no remaining CytomX Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Creative Planning sold 10,505 CytomX Therapeutics shares in Q2 2026, an estimated $49.4K.
  • Creative Planning first reported a position in CytomX Therapeutics in Q2 2024 and held it in 3 quarters.
  • Creative Planning's CytomX Therapeutics position peaked at $131K in Q2 2024.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.